| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1050758604 |
| P356 | DOI | 10.1038/NRM1498 |
| P3181 | OpenCitations bibliographic resource ID | 955593 |
| P698 | PubMed publication ID | 15520807 |
| P5875 | ResearchGate publication ID | 8199334 |
| P2093 | author name string | Marais R | |
| Karasarides M | |||
| Wellbrock C | |||
| P2860 | cites work | Craf-1 protein kinase is essential for mouse development. | Q51990813 |
| Raf-1-associated Protein Phosphatase 2A as a Positive Regulator of Kinase Activation | Q57711698 | ||
| Requirement of Ras-GTP-Raf Complexes for Activation of Raf-1 by Protein Kinase C | Q57979874 | ||
| Regulation of Ras·GTP Loading and Ras-Raf Association in Neonatal Rat Ventricular Myocytes by G Protein-coupled Receptor Agonists and Phorbol Ester | Q58001211 | ||
| Phosphatidylinositol 3-kinase regulates Raf1 through Pak phosphorylation of serine 338 | Q61640742 | ||
| Hypertrophic Agonists Stimulate the Activities of the Protein Kinases c-Raf and A-Raf in Cultured Ventricular Myocytes | Q63208072 | ||
| Role of Raf in vascular protection from distinct apoptotic stimuli | Q73617199 | ||
| The complete coding sequence of the human A-raf-1 oncogene and transforming activity of a human A-raf carrying retrovirus | Q22254864 | ||
| Dynamic changes in C-Raf phosphorylation and 14-3-3 protein binding in response to growth factor stimulation: differential roles of 14-3-3 protein binding sites | Q24302442 | ||
| Endothelial apoptosis in Braf-deficient mice | Q24314857 | ||
| Bcl-2 targets the protein kinase Raf-1 to mitochondria | Q24321753 | ||
| Raf-1 physically interacts with Rb and regulates its function: a link between mitogenic signaling and cell cycle regulation | Q24522903 | ||
| Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation | Q24534094 | ||
| S338 phosphorylation of Raf-1 is independent of phosphatidylinositol 3-kinase and Pak3 | Q24550986 | ||
| Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus | Q24595462 | ||
| Bcl-2 interacting protein, BAG-1, binds to and activates the kinase Raf-1 | Q24617367 | ||
| Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism | Q24633458 | ||
| Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis | Q24791830 | ||
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation | Q28131755 | ||
| Phosphorylation and regulation of Raf by Akt (protein kinase B) | Q28138863 | ||
| Human homologue of Drosophila CNK interacts with Ras effector proteins Raf and Rlf | Q28181747 | ||
| Interaction between active Pak1 and Raf-1 is necessary for phosphorylation and activation of Raf-1 | Q28208695 | ||
| Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions | Q28211695 | ||
| 14-3-3 zeta negatively regulates raf-1 activity by interactions with the Raf-1 cysteine-rich domain | Q28246442 | ||
| Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF | Q28251989 | ||
| Murine Ksr interacts with MEK and inhibits Ras-induced transformation | Q28258869 | ||
| Serine- and threonine-specific protein kinase activities of purified gag-mil and gag-raf proteins | Q28268508 | ||
| A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity | Q28276506 | ||
| Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation | Q28301118 | ||
| MEK kinase activity is not necessary for Raf-1 function | Q28362229 | ||
| The protein kinase Pak3 positively regulates Raf-1 activity through phosphorylation of serine 338 | Q28570374 | ||
| Association of MEK1 with p21ras.GMPPNP is dependent on B-Raf | Q28583306 | ||
| Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis | Q28589059 | ||
| Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak | Q28609071 | ||
| Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites | Q28609103 | ||
| Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation | Q28609129 | ||
| Conditionally oncogenic forms of the A-Raf and B-Raf protein kinases display different biological and biochemical properties in NIH 3T3 cells | Q28609131 | ||
| The mitogen-activated protein kinase cascade is activated by B-Raf in response to nerve growth factor through interaction with p21ras | Q28609138 | ||
| Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases | Q28609156 | ||
| Regulation of MAP Kinase Signaling Modules by Scaffold Proteins in Mammals | Q29619598 | ||
| Inhibition of the EGF-Activated MAP Kinase Signaling Pathway by Adenosine 3′,5′-Monophosphate | Q30464735 | ||
| Raf and the road to cell survival: a tale of bad spells, ring bearers and detours | Q33193874 | ||
| Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells | Q33940377 | ||
| Different protein kinase C isoforms determine growth factor specificity in neuronal cells | Q33964695 | ||
| Positive and negative regulation of Raf kinase activity and function by phosphorylation | Q34080535 | ||
| 14-3-3 proteins: active cofactors in cellular regulation by serine/threonine phosphorylation | Q34439988 | ||
| Fidelity and spatio-temporal control in MAP kinase (ERKs) signalling | Q34815988 | ||
| Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. | Q35117306 | ||
| Ras proteins: different signals from different locations | Q35120159 | ||
| CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK) | Q35581817 | ||
| Actively transcribed genes in the raf oncogene group, located on the X chromosome in mouse and human | Q35608836 | ||
| Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation | Q35688302 | ||
| Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. | Q36572588 | ||
| Raf-1 protein kinase activates the NF-kappa B transcription factor by dissociating the cytoplasmic NF-kappa B-I kappa B complex | Q36582453 | ||
| The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. | Q36681724 | ||
| Critical Tyrosine Residues Regulate the Enzymatic and Biological Activity of Raf-1 Kinase | Q36826443 | ||
| Structure and biological activity of human homologs of the raf/mil oncogene | Q36890496 | ||
| Embryonic lethality and fetal liver apoptosis in mice lacking the c-raf-1 gene | Q39645041 | ||
| Cyclic AMP-dependent kinase regulates Raf-1 kinase mainly by phosphorylation of serine 259. | Q39674554 | ||
| Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms | Q39674723 | ||
| 14-3-3 antagonizes Ras-mediated Raf-1 recruitment to the plasma membrane to maintain signaling fidelity | Q39695510 | ||
| Negative regulation of Raf-1 by phosphorylation of serine 621. | Q40019933 | ||
| B-RAF is a therapeutic target in melanoma | Q40543086 | ||
| B-raf, a new member of the raf family, is activated by DNA rearrangement | Q40650163 | ||
| MAP kinases ERK1 and ERK2: pleiotropic enzymes in a ubiquitous signaling network | Q40675146 | ||
| ERK signalling and oncogene transformation are not impaired in cells lacking A-Raf | Q40753319 | ||
| Critical contribution of linker proteins to Raf kinase activation | Q40763817 | ||
| Erythropoietin-stimulated Raf-1 tyrosine phosphorylation is associated with the tyrosine kinase Lyn in J2E erythroleukemic cells | Q40767486 | ||
| Phosphorylation site specificity of the Pak-mediated regulation of Raf-1 and cooperativity with Src. | Q40803062 | ||
| Mitogenic signaling of Ras is regulated by differential interaction with Raf isozymes | Q40904290 | ||
| A phosphatidylinositol 3-kinase-dependent pathway that differentially regulates c-Raf and A-Raf | Q40969113 | ||
| Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase | Q41093702 | ||
| Characterization of IkappaB kinases. IkappaB-alpha is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate | Q41192610 | ||
| How Ras-related proteins talk to their effectors | Q41331175 | ||
| Functional mapping of the N-terminal regulatory domain in the human Raf-1 protein kinase | Q42477600 | ||
| Phosphorylation of serine 43 is not required for inhibition of c-Raf kinase by the cAMP-dependent protein kinase. | Q42800539 | ||
| Protein kinase A blocks Raf-1 activity by stimulating 14-3-3 binding and blocking Raf-1 interaction with Ras. | Q42800762 | ||
| Microtubule integrity regulates Pak leading to Ras-independent activation of Raf-1. insights into mechanisms of Raf-1 activation | Q43556620 | ||
| Phosphorylation of Raf-1 by p21-activated kinase 1 and Src regulates Raf-1 autoinhibition | Q44292880 | ||
| Serine 338 phosphorylation is dispensable for activation of c-Raf1. | Q44355364 | ||
| Homologous cell-derived oncogenes in avian carcinoma virus MH2 and murine sarcoma virus 3611. | Q45797135 | ||
| Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene. | Q45971337 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 875-85 | |
| P577 | publication date | 2004-11-01 | |
| P1433 | published in | Nature Reviews Molecular Cell Biology | Q1573120 |
| P1476 | title | The RAF proteins take centre stage | |
| P478 | volume | 5 |
| Q38220879 | "RAF" neighborhood: protein-protein interaction in the Raf/Mek/Erk pathway |
| Q35566220 | 14-3-3 Proteins: diverse functions in cell proliferation and cancer progression |
| Q54645685 | 1H, 13C, 15N backbone and side-chain resonance assignments of the human Raf-1 kinase inhibitor protein. |
| Q28647625 | A Combined Pharmacophore Modeling, 3D QSAR and Virtual Screening Studies on Imidazopyridines as B-Raf Inhibitors |
| Q92376061 | A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors |
| Q34649122 | A KSR/CNK complex mediated by HYP, a novel SAM domain-containing protein, regulates RAS-dependent RAF activation in Drosophila |
| Q35600821 | A MEK-independent role for CRAF in mitosis and tumor progression. |
| Q43543397 | A Mek1-Mek2 heterodimer determines the strength and duration of the Erk signal |
| Q54990524 | A Network Pharmacology Approach to Uncover the Multiple Mechanisms of Hedyotis diffusa Willd. on Colorectal Cancer. |
| Q91923527 | A Premature Stop Codon in RAF1 Is the Priority Candidate Causative Mutation of the Inherited Chicken Wingless-2 Developmental Syndrome |
| Q35885652 | A RasGTP-induced conformational change in C-RAF is essential for accurate molecular recognition |
| Q91787280 | A Review of the Molecular Pathways Involved in Resistance to BRAF Inhibitors in Patients with Advanced-Stage Melanoma |
| Q34259205 | A brief history of melanoma: from mummies to mutations |
| Q27865239 | A dimerization-dependent mechanism drives RAF catalytic activation |
| Q51636999 | A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors. |
| Q28541015 | A functional screen reveals an extensive layer of transcriptional and splicing control underlying RAS/MAPK signaling in Drosophila |
| Q93018032 | A model for RAS mutation patterns in cancers: finding the sweet spot |
| Q53155404 | A novel HRAS substitution (c.266C>G; p.S89C) resulting in decreased downstream signaling suggests a new dimension of RAS pathway dysregulation in human development. |
| Q38267947 | A novel MCF-10A line allowing conditional oncogene expression in 3D culture |
| Q36739904 | A novel role for Cdk1/cyclin B in regulating B-raf activation at mitosis |
| Q34402062 | A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF. |
| Q43525317 | A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma |
| Q53389706 | A phase I/Ib study of trametinib (GSK1120212) alone and in combination with gemcitabine in Japanese patients with advanced solid tumors. |
| Q24319503 | A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity |
| Q34170309 | A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia. |
| Q37484359 | A two-stage association study suggests BRAP as a susceptibility gene for schizophrenia |
| Q33413060 | A-RAF kinase functions in ARF6 regulated endocytic membrane traffic |
| Q38618036 | A-Raf: A new star of the family of raf kinases |
| Q39290058 | ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers |
| Q91530411 | ARAF recurrent mutation causes central conducting lymphatic anomaly treatable with a MEK inhibitor |
| Q33778841 | ATP-sensitive potassium (KATP) channel openers diazoxide and nicorandil lower intraocular pressure by activating the Erk1/2 signaling pathway |
| Q59791008 | Aberrant RNA Splicing in Cancer and Drug Resistance |
| Q36152396 | Aberrant expression of COT is related to recurrence of papillary thyroid cancer |
| Q27335279 | Ablation of BRaf impairs neuronal differentiation in the postnatal hippocampus and cerebellum |
| Q36831210 | Absence of BRAF exon 15 mutations in multiple myeloma and Waldenström's macroglobulinemia questions its validity as a therapeutic target in plasma cell neoplasias |
| Q39999843 | Absence of K-Ras Reduces Proliferation and Migration But Increases Extracellular Matrix Synthesis in Fibroblasts |
| Q58796907 | Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma |
| Q33945989 | Activated BRAF induces gliomas in mice when combined with Ink4a/Arf loss or Akt activation. |
| Q50426367 | Activated Braf induces esophageal dilation and gastric epithelial hyperplasia in mice. |
| Q33945972 | Activated MEK cooperates with Ink4a/Arf loss or Akt activation to induce gliomas in vivo |
| Q33723645 | Activating K-Ras mutations outwith 'hotspot' codons in sporadic colorectal tumours - implications for personalised cancer medicine |
| Q38743591 | Activation kinetics of RAF protein in the ternary complex of RAF, RAS-GTP, and kinase on the plasma membrane of living cells: single-molecule imaging analysis |
| Q41680604 | Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence. |
| Q28069018 | Adapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in Melanoma |
| Q36361483 | Advances in ethylene signalling: protein complexes at the endoplasmic reticulum membrane |
| Q38091649 | Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring |
| Q39102460 | Allosteric activation of functionally asymmetric RAF kinase dimers |
| Q38817910 | Allosteric modulators of MEK1: drug design and discovery |
| Q38752000 | An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling |
| Q28607031 | An Investigation of Molecular Docking and Molecular Dynamic Simulation on Imidazopyridines as B-Raf Kinase Inhibitors |
| Q35071050 | An RNAi-based dimorphic genetic screen identified the double bromodomain protein BET-1 as a sumo-dependent attenuator of RAS-mediated signalling |
| Q34985294 | An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila. |
| Q40792412 | Analysis of IDH1-R132 mutation, BRAF V600 mutation and KIAA1549-BRAF fusion transcript status in central nervous system tumors supports pediatric tumor classification |
| Q39979628 | Analysis of Ret knockin mice reveals a critical role for IKKs, but not PI 3-K, in neurotrophic factor-induced survival of sympathetic neurons. |
| Q92961815 | Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q36815556 | Araf kinase antagonizes Nodal-Smad2 activity in mesendoderm development by directly phosphorylating the Smad2 linker region |
| Q38909365 | Aspafilioside B induces G2/M cell cycle arrest and apoptosis by up-regulating H-Ras and N-Ras via ERK and p38 MAPK signaling pathways in human hepatoma HepG2 cells |
| Q92527986 | Atypical BRAF and NRAS Mutations in Mucosal Melanoma |
| Q21134717 | B-RAF mutant alleles associated with Langerhans cell histiocytosis, a granulomatous pediatric disease |
| Q53321121 | B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. |
| Q28585363 | B-Raf is required for positive selection and survival of DP cells, but not for negative selection of SP cells |
| Q38155724 | B-Raf mutation: a key player in molecular biology of cancer. |
| Q34044770 | B-Raf regulation of integrin α4β1-mediated resistance to shear stress through changes in cell spreading and cytoskeletal association in T cells |
| Q28476616 | B-raf alternative splicing is dispensable for development but required for learning and memory associated with the hippocampus in the adult mouse |
| Q41983817 | BAD contributes to RAF-mediated proliferation and cooperates with B-RAF-V600E in cancer signaling |
| Q36403102 | BAFF regulates B cell survival by downregulating the BH3-only family member Bim via the ERK pathway |
| Q40308404 | BCR/ABL and IL-3 activate Rap1 to stimulate the B-Raf/MEK/Erk and Akt signaling pathways and to regulate proliferation, apoptosis, and adhesion |
| Q48218708 | BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy |
| Q40070685 | BRAF and RAS Mutations in Sporadic and Secondary Pyogenic Granuloma |
| Q34286030 | BRAF inactivation drives aneuploidy by deregulating CRAF |
| Q92893698 | BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS |
| Q38088737 | BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma |
| Q28543370 | BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implications |
| Q36921234 | BRAF(E600) in benign and malignant human tumours |
| Q37399265 | BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells |
| Q38259819 | Bench to bedside: mechanistic principles of targeting the RAF kinase in melanoma |
| Q24307524 | Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice |
| Q64951143 | Biological Rationale for Targeting MEK/ERK Pathways in Anti-Cancer Therapy and to Potentiate Tumour Responses to Radiation. |
| Q35752270 | Biophysical Characterization of Essential Phosphorylation at the Flexible C-Terminal Region of C-Raf with 14-3-3ζ Protein. |
| Q38709785 | Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies |
| Q97418618 | Blocking C-Raf alleviated high-dose small-volume radiation-induced epithelial mesenchymal transition in mice lung |
| Q38716283 | Braf V600E mutation in melanoma: translational current scenario. |
| Q39873596 | Braf(V600E) cooperates with Pten loss to induce metastatic melanoma |
| Q39143850 | C-RAF mutations confer resistance to RAF inhibitors |
| Q30664961 | C-Raf deficiency leads to hearing loss and increased noise susceptibility |
| Q37723811 | C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity |
| Q33647423 | CD209a expression on dendritic cells is critical for the development of pathogenic Th17 cell responses in murine schistosomiasis |
| Q27649887 | CNK and HYP form a discrete dimer by their SAM domains to mediate RAF kinase signaling |
| Q34413075 | CNK1 is a scaffold protein that regulates Src-mediated Raf-1 activation |
| Q41825679 | CRAF autophosphorylation of serine 621 is required to prevent its proteasome-mediated degradation |
| Q27865262 | Calcium/calmodulin-dependent protein kinase II (CaMKII) phosphorylates Raf-1 at serine 338 and mediates Ras-stimulated Raf-1 activation. |
| Q36819371 | Cancer cell signaling pathways targeted by spice-derived nutraceuticals |
| Q34002709 | Cancer driver mutations in protein kinase genes |
| Q54543161 | Cancer: A drug-resistant duo. |
| Q43283512 | Carbohydrate-specific signaling through the DC-SIGN signalosome tailors immunity to Mycobacterium tuberculosis, HIV-1 and Helicobacter pylori |
| Q38268502 | Catalytic mechanisms and regulation of protein kinases |
| Q34564806 | Cdc37 interacts with the glycine-rich loop of Hsp90 client kinases |
| Q30160092 | Cdc42 induces activation loop phosphorylation and membrane targeting of mixed lineage kinase 3. |
| Q34225871 | Change or die: targeting adaptive signaling to kinase inhibition in cancer cells |
| Q33725691 | Changed genome heterochromatinization upon prolonged activation of the Raf/ERK signaling pathway |
| Q33740213 | Characterization of the B-Raf interactome in mouse hippocampal neuronal cells |
| Q89538397 | Characterization of the Golgi scaffold protein PAQR3, and its role in tumor suppression and metabolic pathway compartmentalization |
| Q37004639 | Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives |
| Q27727954 | Chemically Linked Vemurafenib Inhibitors Promote an Inactive BRAFV600E Conformation |
| Q30554996 | Chronic itch development in sensory neurons requires BRAF signaling pathways |
| Q37691245 | Clinical application of high-throughput genomic technologies for treatment selection in breast cancer |
| Q35820044 | Clinical detection and categorization of uncommon and concomitant mutations involving BRAF. |
| Q64055605 | Clinical development of targeted and immune based anti-cancer therapies |
| Q58376287 | Clinical profile of comorbidity of rare diseases in a Tunisian patient: a case report associating incontinentia pigmenti and Noonan syndrome |
| Q50421448 | Comparative Transcriptome Analysis Reveals Growth-Related Genes in Juvenile Chinese Sea Cucumber, Russian Sea Cucumber, and Their Hybrids |
| Q37520568 | Comprehensive analysis of long non-coding RNA expression profiles in hepatitis B virus-related hepatocellular carcinoma |
| Q37172538 | Conformational plasticity and navigation of signaling proteins in antigen-activated B lymphocytes |
| Q53352988 | Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. |
| Q30499131 | Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome |
| Q35134415 | Constitutively active Ras negatively regulates Erk MAP kinase through induction of MAP kinase phosphatase 3 (MKP3) in NIH3T3 cells |
| Q37677356 | Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals |
| Q82616798 | Cooperative cell transformation by Myc/Mil(Raf) involves induction of AP-1 and activation of genes implicated in cell motility and metastasis |
| Q29618995 | Coordinating ERK/MAPK signalling through scaffolds and inhibitors |
| Q29614277 | CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer |
| Q29614735 | Critical nodes in signalling pathways: insights into insulin action |
| Q33797782 | Cross-regulation between oncogenic BRAF(V600E) kinase and the MST1 pathway in papillary thyroid carcinoma |
| Q27022355 | Current and future trials of targeted therapies in cutaneous melanoma |
| Q52658584 | Cutaneous melanoma: From pathogenesis to therapy (Review). |
| Q34850793 | Cyclic AMP-mediated cyst expansion |
| Q33840856 | Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival |
| Q39739826 | DA-Raf1, a competent intrinsic dominant-negative antagonist of the Ras-ERK pathway, is required for myogenic differentiation |
| Q21004109 | Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions |
| Q38689614 | Deconstruction of the Ras switching cycle through saturation mutagenesis |
| Q46175551 | Dectin-1 directs T helper cell differentiation by controlling noncanonical NF-kappaB activation through Raf-1 and Syk. |
| Q41285571 | Dendritic cell expression of the C-type lectin receptor CD209a: A novel innate parasite-sensing mechanism inducing Th17 cells that drive severe immunopathology in murine schistosome infection |
| Q37640384 | Deregulation of microRNA expression in thyroid tumors |
| Q33588217 | Design and Development of Fluorescent Vemurafenib Analogs for In Vivo Imaging |
| Q93057265 | Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF |
| Q36189476 | Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization |
| Q33861173 | Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma |
| Q42683550 | Diacylglycerol kinase eta augments C-Raf activity and B-Raf/C-Raf heterodimerization. |
| Q37620399 | Diagnostic markers and prognostic factors in thyroid cancer |
| Q35083732 | Differential Regulation of RasGAPs in Cancer. |
| Q48362048 | Differential mRNA distribution of components of the ERK/MAPK signalling cascade in the adult mouse brain |
| Q24674150 | Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms |
| Q50643518 | Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration. |
| Q34440570 | Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms |
| Q24294914 | Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors |
| Q50538898 | Dissecting Cell-Fate Determination Through Integrated Mathematical Modeling of the ERK/MAPK Signaling Pathway. |
| Q50292937 | Dissociation of RAS:RAF complex |
| Q52673512 | Downregulation of castor zinc finger 1 predicts poor prognosis and facilitates hepatocellular carcinoma progression via MAPK/ERK signaling. |
| Q33752617 | Drosophila Raf's N terminus contains a novel conserved region and can contribute to torso RTK signaling. |
| Q34653547 | Drug safety evaluation of vemurafenib in the treatment of melanoma. |
| Q39362619 | EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib |
| Q39561513 | ERK and PDE4 cooperate to induce RAF isoform switching in melanoma |
| Q35385732 | ERK crosstalks with 4EBP1 to activate cyclin D1 translation during quinol-thioether-induced tuberous sclerosis renal cell carcinoma |
| Q50504024 | ERK phosphorylation and nuclear accumulation: insights from single-cell imaging. |
| Q47807637 | ERK signalling as a regulator of cell motility |
| Q100723196 | ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesis |
| Q50954724 | Early Vaginal Opening in Juvenile Female Rats Given BRAF-Inhibitor Dabrafenib Is Not Associated with Early Physiologic Sexual Maturation. |
| Q37875379 | Early inhibitors of human cytomegalovirus: state-of-art and therapeutic perspectives |
| Q36640274 | Effects of Raf dimerization and its inhibition on normal and disease-associated Raf signaling |
| Q37404768 | Effects of butyltins on mitogen-activated-protein kinase kinase kinase and Ras activity in human natural killer cells |
| Q36748140 | Electrostatic interactions positively regulate K-Ras nanocluster formation and function |
| Q40380155 | Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation |
| Q36833572 | Endothelial RAF1/ERK activation regulates arterial morphogenesis. |
| Q36491749 | Essential role of B-Raf in oligodendrocyte maturation and myelination during postnatal central nervous system development |
| Q27310996 | Expression of B-RAF V600E in type II pneumocytes causes abnormalities in alveolar formation, airspace enlargement and tumor formation in mice |
| Q37093107 | Expression of endogenous oncogenic V600EB-raf induces proliferation and developmental defects in mice and transformation of primary fibroblasts |
| Q35760876 | Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. |
| Q51150179 | Extracellular signal-regulated kinase (ERK) expression and activation in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival. |
| Q37702398 | Extracellular signal-regulated kinase 1/2 (ERK1/2) signaling in cardiac hypertrophy |
| Q53349753 | Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells. |
| Q34544759 | Extracellular signal-regulated kinases 1 and 2 regulate the balance between eccentric and concentric cardiac growth |
| Q26800200 | Extracellular signal-regulated kinases 1/2 as regulators of cardiac hypertrophy |
| Q24296333 | FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice |
| Q24296283 | FAM83B mediates EGFR- and RAS-driven oncogenic transformation |
| Q34041856 | Ferroptosis, a new form of cell death relevant to the medical treatment of cancer |
| Q33838859 | Flavonoids, Thyroid Iodide Uptake and Thyroid Cancer-A Review |
| Q41785401 | Formation of endothelial lumens requires a coordinated PKCepsilon-, Src-, Pak- and Raf-kinase-dependent signaling cascade downstream of Cdc42 activation |
| Q41909915 | From autoinhibition to inhibition in trans: the Raf-1 regulatory domain inhibits Rok-alpha kinase activity |
| Q40279488 | Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein |
| Q27865193 | Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy |
| Q37218244 | Galectin-3 modulates Th17 responses by regulating dendritic cell cytokines |
| Q39694616 | Gatekeeper mutations mediate resistance to BRAF-targeted therapies. |
| Q39758482 | Gating of the mitochondrial permeability transition pore by long chain fatty acyl analogs in vivo |
| Q59335317 | Gene prioritization, communality analysis, networking and metabolic integrated pathway to better understand breast cancer pathogenesis |
| Q38186704 | Genetic alterations and personalized medicine in melanoma: progress and future prospects |
| Q28595029 | Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q83937839 | Genetic and pharmacologic dissection of Ras effector utilization in oncogenesis |
| Q37544403 | Genetic risk factors for melanoma |
| Q36563659 | Genetics of melanoma |
| Q37772777 | Genetics of uveal melanoma and cutaneous melanoma: two of a kind? |
| Q56937812 | Genome-wide analysis of human kinases in clathrin- and caveolae/raft-mediated endocytosis |
| Q50917827 | Genomic insights into head and neck cancer. |
| Q33637874 | Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum |
| Q44394416 | Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome |
| Q39890055 | Ginkgo biloba extract EGb 761 exerts anti-angiogenic effects via activation of tyrosine phosphatases |
| Q41884410 | Graded inhibition of oncogenic Ras-signaling by multivalent Ras-binding domains |
| Q40399403 | Growth factors rescue cutaneous melanoma cells from apoptosis induced by knockdown of mutated (V 600 E) B-RAF. |
| Q30010274 | HIV-1 Tat binds to SH3 domains: cellular and viral outcome of Tat/Grb2 interaction |
| Q54683069 | HIV-1 exploits innate signaling by TLR8 and DC-SIGN for productive infection of dendritic cells. |
| Q33998634 | Heat shock protein 90β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells |
| Q24683035 | Hepatitis B virus X protein stimulates the mitochondrial translocation of Raf-1 via oxidative stress |
| Q34572289 | High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma |
| Q83820786 | Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs |
| Q29616397 | Hyperactive Ras in developmental disorders and cancer |
| Q36741572 | IMP modulates KSR1-dependent multivalent complex formation to specify ERK1/2 pathway activation and response thresholds |
| Q24323920 | IQGAP1 integrates Ca2+/calmodulin and B-Raf signaling |
| Q24309982 | IQGAP1 modulates activation of B-Raf |
| Q24655426 | IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis |
| Q90279272 | ITCH as a potential therapeutic target in human cancers |
| Q28648013 | Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding |
| Q27678754 | Identification of a Novel Family of BRAF V600E Inhibitors |
| Q34407252 | Identification of novel in vivo Raf-1 phosphorylation sites mediating positive feedback Raf-1 regulation by extracellular signal-regulated kinase |
| Q24323069 | Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation |
| Q58793747 | Identification of recurrent USP48 and BRAF mutations in Cushing's disease |
| Q64240502 | Immunohistochemical Analysis of BRAF (V600E) Mutation and P16 Expression in Malignant Melanoma in Lagos, Nigeria: A 10-Year Retrospective Study |
| Q41874771 | Immunohistochemistry is highly sensitive and specific for detection of BRAF V600E mutation in pleomorphic xanthoastrocytoma |
| Q26866122 | Impact of BRAF mutation status in the prognosis of cutaneous melanoma: an area of ongoing research |
| Q33613978 | Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling |
| Q24294250 | Impaired Binding of 14-3-3 to C-RAF in Noonan Syndrome Suggests New Approaches in Diseases with Increased Ras Signaling |
| Q36277286 | Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants |
| Q39641932 | Indazolylpyrazolopyrimidine as Highly Potent B-Raf Inhibitors with in Vivo Activity |
| Q39997379 | Inducible BRAF suppression models for melanoma tumorigenesis |
| Q88554448 | Inhibition of Raf1 ameliorates bleomycin-induced pulmonary fibrosis through attenuation of TGF-β1 signaling |
| Q35570948 | Inhibition of the growth of papillary thyroid carcinoma cells by CI-1040. |
| Q35619558 | Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing |
| Q98891376 | Inhibitors of BRAF dimers using an allosteric site |
| Q36625236 | Inhibitors of signal transduction protein kinases as targets for cancer therapy |
| Q27678182 | Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization |
| Q34627656 | Integrating signals from RTKs to ERK/MAPK. |
| Q42826052 | Integrin signaling, cell survival, and anoikis: distinctions, differences, and differentiation |
| Q39134067 | Inter-cellular adhesion disruption and the RAS/RAF and beta-catenin signalling in lung cancer progression |
| Q36403673 | Interaction of CagA with Crk plays an important role in Helicobacter pylori-induced loss of gastric epithelial cell adhesion |
| Q37273093 | Interferon alpha-inducible protein 6 regulates NRASQ61K-induced melanomagenesis and growth |
| Q58759673 | Interrogating the protein interactomes of RAS isoforms identifies PIP5K1A as a KRAS-specific vulnerability |
| Q28576259 | Involvement of acidic fibroblast growth factor in spinal cord injury repair processes revealed by a proteomics approach |
| Q54592678 | Is Raf1 a nexus for cardiac hypertrophic signaling in human disease? |
| Q43985982 | Isoform-specific interaction of C-RAF with mitochondria |
| Q33809881 | Isoproterenol and cAMP block ERK phosphorylation and enhance [Ca2+]i increases and oxygen consumption by muscarinic receptor stimulation in rat parotid and submandibular acinar cells |
| Q37995683 | IκB kinase regulation of the TPL-2/ERK MAPK pathway |
| Q64097770 | K27-linked ubiquitination of BRAF by ITCH engages cytokine response to maintain MEK-ERK signaling |
| Q36819377 | KSR and CNK: two scaffolds regulating RAS-mediated RAF activation |
| Q54154488 | Langerhans cell histiocytosis associated with lymphoma: an incidental finding that is not associated with BRAF or MAP2K1 mutations. |
| Q21202917 | Leopard syndrome |
| Q46120402 | Long-term extracellular signal-related kinase activation following cadmium intoxication is negatively regulated by a protein kinase C-dependent pathway affecting cadmium transport |
| Q91725276 | Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway |
| Q43138421 | Lymphatic fate determination: playing RAF with ERK. |
| Q27005981 | Lymphatic fate specification: an ERK-controlled transcriptional program |
| Q38158991 | Lymphatic vessel abnormalities arising from disorders of Ras signal transduction |
| Q39116774 | Lys63-linked polyubiquitination of BRAF at lysine 578 is required for BRAF-mediated signaling. |
| Q29615542 | MAP kinase signalling pathways in cancer |
| Q33787343 | MAP4K4 is a novel MAPK/ERK pathway regulator required for lung adenocarcinoma maintenance |
| Q38238597 | MAPK pathway inhibition in melanoma: resistance three ways |
| Q37254485 | MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets |
| Q45317142 | MAPK1/MAPK3 signaling |
| Q38210121 | MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation |
| Q36099005 | MEK genomics in development and disease |
| Q34109756 | MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo |
| Q39359514 | MEK inhibitors in oncology: a patent review (2015-Present). |
| Q47105077 | MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway |
| Q51023212 | MYC and RAF: Key Effectors in Cellular Signaling and Major Drivers in Human Cancer. |
| Q35017513 | Macrocyclic inhibitors of hsp90 |
| Q57664796 | Malignant Melanoma–a Genetic Overview |
| Q38005668 | Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update |
| Q38604285 | Mathematical Justification of Expression-Based Pathway Activation Scoring (PAS). |
| Q37727077 | Measurement of constitutive MAPK and PI3K/AKT signaling activity in human cancer cell lines |
| Q39125284 | Measuring ERK Activity Dynamics in Single Living Cells Using FRET Biosensors |
| Q27685364 | Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers |
| Q35693850 | Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma |
| Q38909541 | Mechanisms and regulation of endothelial VEGF receptor signalling. |
| Q37350013 | Mechanisms involved in the nutritional regulation of mRNA translation: features of the avian model |
| Q37785803 | Mechanistic principles of RAF kinase signaling |
| Q39799542 | Melanocortin 1 receptor mutations impact differentially on signalling to the cAMP and the ERK mitogen-activated protein kinase pathways |
| Q36742015 | Melanoma biology and new targeted therapy |
| Q38146707 | Melanoma mutagenesis and aberrant cell signaling |
| Q99551742 | Melatonin promotes Schwann cell dedifferentiation and proliferation through the Ras/Raf/ERK and MAPK pathways, and glial cell-derived neurotrophic factor expression |
| Q47568436 | Membrane-associated Ras dimers are isoform-specific: K-Ras dimers differ from H-Ras dimers |
| Q47269342 | Metabolic stress regulates ERK activity by controlling KSR-RAF heterodimerization |
| Q38394400 | Microphthalmia-associated transcription factor in melanoma development and MAP-kinase pathway targeted therapy. |
| Q35191037 | Mitogen and stress activated kinases act co-operatively with CREB during the induction of human cytomegalovirus immediate-early gene expression from latency. |
| Q28548302 | Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation |
| Q33713373 | Mixed lineage kinases activate MEK independently of RAF to mediate resistance to RAF inhibitors |
| Q64996278 | Moderate aerobic exercise training decreases middle-aged induced pathologic cardiac hypertrophy by improving Klotho expression, MAPK signaling pathway, and oxidative stress status in Wistar rats. |
| Q28538778 | Modification, biological evaluation and 3D QSAR studies of novel 2-(1,3-diaryl- 4,5-dihydro-1H-pyrazol-5-yl)phenol derivatives as inhibitors of B-Raf kinase |
| Q26745320 | Modulation of Autophagy by Sorafenib: Effects on Treatment Response |
| Q53205249 | Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic Melanoma. |
| Q39164873 | Molecular Pathways: Maintaining MAPK Inhibitor Sensitivity by Targeting Nonmutational Tolerance. |
| Q48785966 | Molecular characterization of a t(2;6) balanced translocation that is associated with a complex phenotype and leads to truncation of the TCBA1 gene |
| Q41855920 | Molecular pathways underlying cardiac remodeling during pathophysiological stimulation |
| Q54977434 | Molecular recognition of RAS/RAF complex at the membrane: Role of RAF cysteine-rich domain. |
| Q38966698 | Molecular signaling cascades involved in nonmelanoma skin carcinogenesis |
| Q35023456 | Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers |
| Q26795735 | Multiple Molecular Pathways in Melanomagenesis: Characterization of Therapeutic Targets |
| Q36255099 | Multiplexing PKA and ERK1&2 kinases FRET biosensors in living cells using single excitation wavelength dual colour FLIM. |
| Q28259285 | Mutant B-RAF signaling and cyclin D1 regulate Cks1/S-phase kinase-associated protein 2-mediated degradation of p27Kip1 in human melanoma cells |
| Q36180749 | Mutant K-RAS Promotes Invasion and Metastasis in Pancreatic Cancer Through GTPase Signaling Pathways |
| Q33308740 | Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy |
| Q92630701 | Mutations That Confer Drug-Resistance, Oncogenicity and Intrinsic Activity on the ERK MAP Kinases-Current State of the Art |
| Q40319765 | Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma |
| Q52584709 | Myeloid cell deficiency of p38γ/p38δ protects against candidiasis and regulates antifungal immunity. |
| Q36512298 | N terminus of ASPP2 binds to Ras and enhances Ras/Raf/MEK/ERK activation to promote oncogene-induced senescence |
| Q54979742 | N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. |
| Q47688064 | New perspectives for targeting RAF kinase in human cancer. |
| Q24299821 | Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia |
| Q37610817 | Non-redundancy within the RAS oncogene family: insights into mutational disparities in cancer |
| Q27001641 | Noonan syndrome |
| Q34678373 | Noonan syndrome and clinically related disorders |
| Q33806161 | Noonan syndrome: clinical aspects and molecular pathogenesis |
| Q37343475 | Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway |
| Q37856375 | Occupational hazards: allosteric regulation of protein kinases through the nucleotide-binding pocket |
| Q26739777 | Oncogenes: The Passport for Viral Oncolysis Through PKR Inhibition |
| Q37274568 | Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation |
| Q33581231 | Oncogenic BRAFV600E induces expression of neuronal differentiation marker MAP2 in melanoma cells by promoter demethylation and down-regulation of transcription repressor HES1. |
| Q42445553 | Oncogenic HRAS mutations cause prolonged PI3K signaling in response to epidermal growth factor in fibroblasts of patients with Costello syndrome |
| Q38762520 | Oncogenic KRAS and BRAF Drive Metabolic Reprogramming in Colorectal Cancer. |
| Q27852873 | Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma |
| Q39648474 | Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors |
| Q43298157 | Overcoming resistance to BRAF inhibitors. |
| Q36562077 | Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma |
| Q39061591 | Overexpression of miR-145 increases the sensitivity of vemurafenib in drug-resistant colo205 cell line |
| Q59129460 | Overview of MDM2 and B-RAF Expression in Gastric Lesions |
| Q34074910 | Oxidation of HRas cysteine thiols by metabolic stress prevents palmitoylation in vivo and contributes to endothelial cell apoptosis |
| Q50292321 | PAK phosphorylates p21 RAF1 on S338 |
| Q24337364 | PHLPP is a negative regulator of RAF1, which reduces colorectal cancer cell motility and prevents tumor progression in mice |
| Q39027993 | PHLPPing through history: a decade in the life of PHLPP phosphatases |
| Q37931976 | PI3K-Akt-mTOR and MAPK signaling pathways in polycystic ovarian syndrome, uterine leiomyomas and endometriosis: an update |
| Q21328702 | PPAR-γ agonists and their effects on IGF-I receptor signaling: Implications for cancer |
| Q24310359 | PTPIP51, a novel 14-3-3 binding protein, regulates cell morphology and motility via Raf-ERK pathway |
| Q37697778 | Paradoxical oncogenesis--the long-term effects of BRAF inhibition in melanoma |
| Q33679204 | Paragangliomas/Pheochromocytomas: clinically oriented genetic testing |
| Q33618711 | Parthenolide suppresses non-small cell lung cancer GLC-82 cells growth via B-Raf/MAPK/Erk pathway |
| Q37590321 | Pathogen recognition by DC-SIGN shapes adaptive immunity |
| Q38025628 | Personalized medicine in metastatic non-small-cell lung cancer: promising targets and current clinical trials |
| Q54308330 | Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma. |
| Q27852623 | Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial. |
| Q92508283 | Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations |
| Q36452213 | Phosphatidylenthanolamine Binding Protein aka Raf Kinase Inhibitor Protein: A Brief History of Its Discovery and the Remarkable Diversity of Biological Functions |
| Q42215577 | Phosphatidylserine-dependent neuroprotective signaling promoted by docosahexaenoic acid |
| Q42512195 | Phosphorylation of the C-Raf N-region promotes Raf dimerization |
| Q26766708 | Phytochemicals for the Management of Melanoma |
| Q35164331 | Piperine causes G1 phase cell cycle arrest and apoptosis in melanoma cells through checkpoint kinase-1 activation |
| Q39804200 | Plasma membrane nanoswitches generate high-fidelity Ras signal transduction |
| Q90579775 | Polyacrylamide/Phytic Acid/Polydopamine Hydrogel as an Efficient Substrate for Electrochemical Enrichment of Circulating Cell-Free DNA from Blood Plasma |
| Q35539933 | Polyoma and SV40 proteins differentially regulate PP2A to activate distinct cellular signaling pathways involved in growth control |
| Q46458312 | Positive regulation of A-RAF by phosphorylation of isoform-specific hinge segment and identification of novel phosphorylation sites |
| Q52724679 | Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas. |
| Q90469867 | Prediction of sorafenib treatment-related gene expression for hepatocellular carcinoma: preoperative MRI and histopathological correlation |
| Q38614956 | Principles of K-Ras effector organization and the role of oncogenic K-Ras in cancer initiation through G1 cell cycle deregulation |
| Q40393756 | Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration |
| Q28567709 | Protein arginine methyltransferase 5 regulates ERK1/2 signal transduction amplitude and cell fate through CRAF |
| Q24323910 | Protein kinase WNK2 inhibits cell proliferation by negatively modulating the activation of MEK1/ERK1/2 |
| Q37156628 | Protein scaffolds in MAP kinase signalling |
| Q41619411 | Pseudorabies virus triggers glycoprotein gE-mediated ERK1/2 activation and ERK1/2-dependent migratory behavior in T cells |
| Q54683502 | QM/MM based 3D QSAR models for potent B-Raf inhibitors. |
| Q29620033 | RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) |
| Q27659493 | RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth |
| Q47144509 | RAF inhibitors promote RAS-RAF interaction by allosterically disrupting RAF autoinhibition |
| Q29616828 | RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF |
| Q30477716 | RAF kinase activity regulates neuroepithelial cell proliferation and neuronal progenitor cell differentiation during early inner ear development |
| Q91739538 | RAF kinase dimerization: implications for drug discovery and clinical outcomes |
| Q43167319 | RAF modulators and methods of use. |
| Q28289378 | RAF protein-serine/threonine kinases: Structure and regulation |
| Q42572365 | RAF translocations expand cancer targets |
| Q39289867 | RAF-targeted therapy for hepatocellular carcinoma in the regenerating liver |
| Q45317143 | RAF/MAP kinase cascade |
| Q50292320 | RAF1 binds p21 RAS:GTP |
| Q36398735 | RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies |
| Q33215530 | RNA interference: from gene silencing to gene-specific therapeutics |
| Q39912763 | RNAi-mediated inhibition of Raf-1 leads to decreased angiogenesis and tumor growth in gastric cancer |
| Q38652041 | Radiotherapy with BRAF inhibitor therapy for melanoma: progress and possibilities |
| Q80149165 | Raf 1 represses expression of the tight junction protein occludin via activation of the zinc-finger transcription factor slug |
| Q24316181 | Raf family kinases: old dogs have learned new tricks |
| Q36498712 | Raf kinase inhibitor protein regulation of raf and MAPK signaling |
| Q40151962 | Raf kinase signaling functions in sensory neuron differentiation and axon growth in vivo |
| Q28237793 | Raf kinases in cancer-roles and therapeutic opportunities |
| Q36002845 | Raf kinases: function, regulation and role in human cancer |
| Q36559414 | Raf kinases: oncogenesis and drug discovery |
| Q40421041 | Raf-1 serine 338 phosphorylation plays a key role in adhesion-dependent activation of extracellular signal-regulated kinase by epidermal growth factor. |
| Q27692653 | Raf-interactome in tuning the complexity and diversity of Raf function |
| Q36206487 | RanBPM expression regulates transcriptional pathways involved in development and tumorigenesis. |
| Q34568332 | Random parameter sampling of a generic three-tier MAPK cascade model reveals major factors affecting its versatile dynamics |
| Q48514183 | Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform. |
| Q37548931 | Ras signaling and therapies |
| Q49874520 | Ras-Mediated Activation of the Raf Family Kinases |
| Q37024839 | Recent discoveries in the genetics of melanoma and their therapeutic implications |
| Q33906093 | Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. |
| Q42910805 | Reduction of Raf kinase inhibitor protein expression by Bcr-Abl contributes to chronic myelogenous leukemia proliferation |
| Q64898821 | Regression of BRAF V600E mutant adult glioblastoma after primary combined BRAF-MEK inhibitor targeted therapy: a report of two cases. |
| Q28392677 | Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase |
| Q28580581 | Regulation and role of Raf-1/B-Raf heterodimerization |
| Q36738312 | Regulation of MAPKs by growth factors and receptor tyrosine kinases |
| Q24320264 | Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins |
| Q24314069 | Regulation of RKIP binding to the N-region of the Raf-1 kinase |
| Q41978120 | Regulation of cellular proliferation, differentiation and cell death by activated Raf. |
| Q33955047 | Regulation of mTORC1 signaling by pH |
| Q30156053 | Regulation of mixed-lineage kinase activation in JNK-dependent morphogenesis |
| Q46856695 | Regulation of protein kinase C delta by phorbol ester, endothelin-1, and platelet-derived growth factor in cardiac myocytes |
| Q28577191 | Regulation of the Raf-MEK-ERK pathway by protein phosphatase 5 |
| Q24303940 | Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas |
| Q33651779 | Resistance to Raf inhibition in cancer |
| Q41878891 | Rethinking the role of oncogenes in papillary thyroid cancer initiation |
| Q55492453 | Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAFV600E-Specific Inhibitor). |
| Q34657323 | Review of histopathological and molecular prognostic features in colorectal cancer |
| Q28248759 | Rheb inhibits C-raf activity and B-raf/C-raf heterodimerization |
| Q28114950 | Rin GTPase couples nerve growth factor signaling to p38 and b-Raf/ERK pathways to promote neuronal differentiation |
| Q42810717 | Role of group A p21-activated kinases in activation of extracellular-regulated kinase by growth factors |
| Q36217262 | Role of melanoma inhibitor of apoptosis (ML-IAP) protein, a member of the baculoviral IAP repeat (BIR) domain family, in the regulation of C-RAF kinase and cell migration |
| Q36819381 | Role of mitogen-activated protein kinase kinase kinases in signal integration |
| Q36451902 | SHOC2 and CRAF mediate ERK1/2 reactivation in mutant NRAS-mediated resistance to RAF inhibitor |
| Q47144786 | SIRT2 and lysine fatty acylation regulate the transforming activity of K-Ras4a. |
| Q47164217 | SPC24 promotes osteosarcoma progression by increasing EGFR/MAPK signaling |
| Q38961122 | SUMO in Drosophila Development |
| Q21559503 | Salp15 binding to DC-SIGN inhibits cytokine expression by impairing both nucleosome remodeling and mRNA stabilization |
| Q36559220 | Scaffolding protein Grb2-associated binder 1 sustains epidermal growth factor-induced mitogenic and survival signaling by multiple positive feedback loops |
| Q24304936 | Second nature: biological functions of the Raf-1 "kinase" |
| Q36961746 | Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells |
| Q37004743 | Selective Raf inhibition in cancer therapy |
| Q39675037 | Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth |
| Q45317941 | Signal Transduction |
| Q52717934 | Signaling and Function of Interleukin-2 in T Lymphocytes. |
| Q45317943 | Signaling by Receptor Tyrosine Kinases |
| Q34943036 | Signaling from the human melanocortin 1 receptor to ERK1 and ERK2 mitogen-activated protein kinases involves transactivation of cKIT. |
| Q34986405 | Signalling through C-type lectin receptors: shaping immune responses |
| Q41908921 | Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase |
| Q37319491 | Single-molecule superresolution imaging allows quantitative analysis of RAF multimer formation and signaling |
| Q38125504 | Skin toxicity of targeted cancer agents: mechanisms and intervention. |
| Q34432977 | Small G Protein Signaling in Neuronal Plasticity and Memory Formation: The Specific Role of Ras Family Proteins |
| Q37068484 | Small G proteins exhibit pattern sensitivity in MAPK activation during the induction of memory and synaptic facilitation in Aplysia |
| Q33756524 | Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics |
| Q90473651 | Somatic ERK activation during transit amplification is essential for maintaining the synchrony of germline divisions in Drosophila testis |
| Q35570953 | Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement |
| Q34241371 | Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled |
| Q24338512 | Spatial regulation of Raf kinase signaling by RKTG |
| Q42838565 | Spatially dependent dynamic MAPK modulation by the Nde1-Lis1-Brap complex patterns mammalian CNS. |
| Q39817347 | Specific phosphorylation and activation of ERK1c by MEK1b: a unique route in the ERK cascade |
| Q92129011 | Sphingolipid/Ceramide Pathways and Autophagy in the Onset and Progression of Melanoma: Novel Therapeutic Targets and Opportunities |
| Q28563583 | SteC is a Salmonella kinase required for SPI-2-dependent F-actin remodelling |
| Q38309987 | Structural insight into effector proteins of Gram-negative bacterial pathogens that modulate the phosphoproteome of their host |
| Q24302450 | Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling |
| Q54283199 | Study of peripheral BRAF(V600E) mutation as a possible novel marker for papillary thyroid carcinomas. |
| Q48441222 | Sustained activation of M-Ras induced by nerve growth factor is essential for neuronal differentiation of PC12 cells |
| Q39460714 | Synthesis and biological evaluation of novel N, N'-disubstituted urea and thiourea derivatives as potential anti-melanoma agents |
| Q39110584 | Synthesis, biological evaluation and molecular docking of novel 5-phenyl-1H-pyrazol derivatives as potential BRAF(V600E) inhibitors |
| Q37149856 | Systemic targeting inhibitor of kappaB kinase inhibits melanoma tumor growth |
| Q37196175 | Systems-level interactions between insulin-EGF networks amplify mitogenic signaling. |
| Q42650702 | T cell leukemia control via Ras-Raf pathway inhibition with peptides |
| Q64113617 | TARBP2-mediated destabilization of Nanog overcomes sorafenib resistance in hepatocellular carcinoma |
| Q26798443 | Targeted Therapy in Biliary Tract Cancers |
| Q33714000 | Targeted deletion of ERK2 in cardiomyocytes attenuates hypertrophic response but provokes pathological stress induced cardiac dysfunction. |
| Q34222257 | Targeted inhibition of BRAF kinase: opportunities and challenges for therapeutics in melanoma |
| Q36800148 | Targeted therapy for BRAFV600E malignant astrocytoma. |
| Q92663940 | Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy |
| Q37341230 | Targeting Bcl-2 based on the interaction of its BH4 domain with the inositol 1,4,5-trisphosphate receptor. |
| Q38098888 | Targeting MAPK pathway in melanoma therapy |
| Q38272894 | Targeting RAS-ERK signalling in cancer: promises and challenges |
| Q35859282 | Targeting mutant BRAF in melanoma: current status and future development of combination therapy strategies |
| Q40240418 | Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours |
| Q37745182 | Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail |
| Q36278239 | Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy |
| Q36804407 | Targeting the PI3K and MAPK pathways to treat Kaposi's-sarcoma-associated herpes virus infection and pathogenesis |
| Q40154931 | Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. |
| Q29618155 | Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer |
| Q37332559 | The 14-3-3 proteins: integrators of diverse signaling cues that impact cell fate and cancer development |
| Q90374977 | The AMPK inhibitor overcomes the paradoxical effect of RAF inhibitors through blocking phospho-Ser-621 in the C terminus of CRAF |
| Q51013762 | The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function. |
| Q24313905 | The C-terminus of Raf-1 acts as a 14-3-3-dependent activation switch |
| Q33878815 | The CRAL/TRIO and GOLD domain protein TAP-1 regulates RAF-1 activation |
| Q27654846 | The Crystal Structure of BRAF in Complex with an Organoruthenium Inhibitor Reveals a Mechanism for Inhibition of an Active Form of BRAF Kinase |
| Q37903694 | The ERK Cascade: Distinct Functions within Various Subcellular Organelles |
| Q36260506 | The ERK cascade: a prototype of MAPK signaling |
| Q24309261 | The ERK signaling cascade--views from different subcellular compartments |
| Q36283341 | The Kinase Activity-deficient Isoform of the Protein Araf Antagonizes Ras/Mitogen-activated Protein Kinase (Ras/MAPK) Signaling in the Zebrafish Embryo |
| Q37784732 | The MAP Kinase Signaling Cascades: A System of Hundreds of Components Regulates a Diverse Array of Physiological Functions |
| Q36217950 | The RAS-Effector Interface: Isoform-Specific Differences in the Effector Binding Regions |
| Q37996420 | The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches. |
| Q35083727 | The RalGEF-Ral Effector Signaling Network: The Road Less Traveled for Anti-Ras Drug Discovery |
| Q34106285 | The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit |
| Q28075539 | The Role of ERK1/2 in the Development of Diabetic Cardiomyopathy |
| Q90398014 | The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding Protein 4 In Tumors |
| Q36421433 | The SH3 domain of Lck modulates T-cell receptor-dependent activation of extracellular signal-regulated kinase through activation of Raf-1. |
| Q38795069 | The Stress-Response MAP Kinase Signaling in Cardiac Arrhythmias. |
| Q42827990 | The T1790A BRAF mutation (L597Q) in childhood acute lymphoblastic leukemia is a functional oncogene |
| Q57150715 | The Transcription Factor ETV5 Mediates BRAFV600E-Induced Proliferation and TWIST1 Expression in Papillary Thyroid Cancer Cells |
| Q24297793 | The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. |
| Q35878248 | The current state of targeted therapy in melanoma: this time it's personal |
| Q58056531 | The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants |
| Q38559739 | The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma |
| Q34572036 | The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells |
| Q37686994 | The importance of Raf dimerization in cell signaling |
| Q39017645 | The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib |
| Q52739043 | The novel RAF1 mutation p.(Gly361Ala) located outside the kinase domain of the CR3 region in two patients with Noonan syndrome, including one with a rare brain tumor. |
| Q34565488 | The novel SAM domain protein Aveugle is required for Raf activation in the Drosophila EGF receptor signaling pathway |
| Q53697878 | The oxidoreductase p66Shc acts as tumor suppressor in BRAFV600E-transformed cells. |
| Q35131558 | The pore-forming α-toxin from clostridium septicum activates the MAPK pathway in a Ras-c-Raf-dependent and independent manner |
| Q34637951 | The role of BRAF V600 mutation in melanoma |
| Q35001465 | The role of specific mitogen-activated protein kinase signaling cascades in the regulation of steroidogenesis |
| Q47105677 | The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy |
| Q26771844 | The structure and function of NKAIN2-a candidate tumor suppressor |
| Q34275807 | The tumor suppressor DiRas3 forms a complex with H-Ras and C-RAF proteins and regulates localization, dimerization, and kinase activity of C-RAF |
| Q38564090 | The utility of molecular markers in pre-operative assessment of thyroid nodules |
| Q38358817 | The yin-yang of kinase activation and unfolding explains the peculiarity of Val600 in the activation segment of BRAF. |
| Q37632230 | Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications |
| Q37873464 | Therapy for metastatic melanoma: an overview and update |
| Q37353436 | Thinking outside the box about Ras. |
| Q38716887 | Time-resolved Phosphoproteome Analysis of Paradoxical RAF Activation Reveals Novel Targets of ERK. |
| Q48029958 | Timeline metastatic progression: in the wake of the « seed and soil » theory. |
| Q38732942 | Transcriptional and post-translational modifications of B-Raf in quinol-thioether induced tuberous sclerosis renal cell carcinoma |
| Q38160738 | Tumor adaptation and resistance to RAF inhibitors |
| Q38026611 | Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5 |
| Q53246129 | Tyrosine phosphatase SHP-1 is expressed higher in multisystem than in single-system Langerhans cell histiocytosis by immunohistochemistry. |
| Q42811739 | Tyrosine phosphorylation and Ras activation is required for hydrogen peroxide-mediated Raf-1 kinase activation |
| Q36455078 | Understanding the genotype of follicular thyroid tumors |
| Q39407551 | Up-regulation of pro-apoptotic protein Bim and down-regulation of anti-apoptotic protein Mcl-1 cooperatively mediate enhanced tumor cell death induced by the combination of ERK kinase (MEK) inhibitor and microtubule inhibitor |
| Q34641609 | Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanoma |
| Q39770574 | Viral oncolysis that targets Raf-1 signaling control of nuclear transport. |
| Q36069254 | When kinases meet mathematics: the systems biology of MAPK signalling |
| Q28301018 | X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility |
| Q42017919 | c-Myc regulates RNA splicing of the A-Raf kinase and its activation of the ERK pathway |
| Q37776022 | cAMP-dependent protein kinase from Plasmodium falciparum: an update |
| Q37590529 | miR-146a promotes the initiation and progression of melanoma by activating Notch signaling. |
| Q36208479 | miR-195 is a key regulator of Raf1 in thyroid cancer |
| Q36094132 | p38γ and p38δ kinases regulate the Toll-like receptor 4 (TLR4)-induced cytokine production by controlling ERK1/2 protein kinase pathway activation |
Search more.